Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1627
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18601603 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | Final Rejection | ANTECIP BIOVENTURES II LLC |
| 18254828 | LIQUID PESTICIDAL COMPOSITION | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18926122 | COMPOSITIONS CONTAINING A NON-CAFFEINE STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | Final Rejection | AXCESS GLOBAL SCIENCES, LLC |
| 18379033 | USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17923294 | FRUIT FLY CONTROL | Final Rejection | MACQUARIE UNIVERSITY |
| 18007426 | COMBINATION THERAPY FOR INHALATION ADMINISTRATION | Final Rejection | Chemo Research, S.L. |
| 18680052 | Use of Ibezapolstat to Promote Microbiome Health | Non-Final OA | Acurx Pharmaceuticals, Inc. |
| 18009082 | STABLE CYMOXANIL FORMULATIONS | Non-Final OA | Adama Makhteshim Ltd. |
| 18642382 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | Final Rejection | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 17772032 | EXERCISE-INDUCED HEMOLYSIS SUPPRESSANT AND COMPOSITION FOR SUPPRESSING/IMPROVING EXERCISE-INDUCED HEMOLYTIC ANEMIA | Final Rejection | Tokai University Educational System |
| 18564518 | TOPICAL FORMULATION OF DIMETHYLCURCUMIN | Non-Final OA | ANNJI PHARMACEUTICAL CO., LTD. |
| 18103541 | PREVENTION OF DISEASES IN HONEYBEES AND REDUCTION OF PESTICIDE RESIDUES IN BEESWAX | Non-Final OA | Arkema Inc. |
| 17998790 | CANNABIDIOL AS A THERAPEUTIC MODALITY FOR COVID-19 | Final Rejection | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. |
| 17548842 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADER | Non-Final OA | Arvinas Operations, Inc. |
| 18552988 | NOVEL USE OF 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE | Non-Final OA | Hyundai Pharm Co., Ltd. |
| 18272326 | TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME | Non-Final OA | ACTIVE BIOTECH AB |
| 18460197 | USE OF 5-[[4-[2-[5-ACETYLPYRIDIN-2-YL]ETHOXY]BENZYL]-1,3-THIAZOLIDINE-2,4-DIONE AND ITS SALTS | Non-Final OA | Minoryx Therapeutics S.L. |
| 18263092 | TREATMENT OF SLEEP APNEA WITH CBD | Non-Final OA | ZYNERBA PHARMACEUTICALS, INC. |
| 18109410 | MONENSIN LEVELS FOR MODERN DAIRY DIET | Non-Final OA | ELANCO TIERGESUNDHEIT AG |
| 18108985 | NATURALLY-DERIVED SURFACE SANITIZER AND DISINFECTANT | Final Rejection | PRONATURAL BRANDS, LLC |
| 17904625 | A NON-SENSITIZING ANTIMICROBIAL COMPOSITION FOR WATERBORNE COATING COMPOSITIONS | Final Rejection | PERSTORP AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy